Hot Investor Mandate 1: Large Healthcare System Makes Strategic Investments in Personalized Health Technologies

A large not-for-profit healthcare system serves over 2 million people each year has created a strategic investment arm, which launched in 2016 with an inaugural $150M allocation dedicated to investing in innovative companies that fit the healthcare system’s key strategic priorities: safety & quality, analytics, clinical innovations, and technology. The strategic arm focuses on Series A to B funding in innovative companies and will also invest in funds that share the same strategic vision. The firm’s investment sizes typically range from $1-2 million and the firm invests globally. In addition, the firm supports the growth of early-stage companies through an accelerator program.

The firm is focused on personalized health technologies and will consider innovations in medical devices, diagnostics, and healthcare IT/digital health. However, the firm will not invest in therapeutics or Class III (PMA) devices/products. Examples of current investments include a diagnostic company that enables health systems to deliver patient-specific diagnostic and treatment options based on the individual’s DNA, a company developing an automated online platform for patients to better manage their healthcare bills and payments, etc. All technologies must have passed conceptual stage of development and have a valid proof-of-concept.

The firm seek to work with companies that have mitigated technical risk and have achieved initial market validation for their products and technology. The firm will also evaluate companies on the basis of strategic and market fit from a health systems perspective. The firm is a strategic investor and invests in companies in which it intends to use the company’s products or services. The firm has led investment rounds, but generally co-invest with other syndicates. The firm does not always require a board seat in its portfolio companies. The firm’s accelerator program will consider earlier stage companies, including less technical, market and management team development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: Venture Arm of Health Insurance Firm Invests in Healthcare IT, Tech Enabled Services and Diagnostics

A major health insurance firm has formed a collaborative corporate investment vehicle that is based in the US Midwest. The firm is looking to make investments ranging from $5 – $15 million over the lifetime of the investment in stages ranging anywhere from seed to buyout. The firm looks to invest in companies of strategic interest to the payer while also seeking strong financial returns. The firm is actively reviewing new opportunities and will consider companies located around the globe.

The firm is looking to invest in sectors of Healthcare IT, Services, and Diagnostics and to a lesser extent wearable devices. The firm is most interested in companies that are have reached or are very near FDA approval and are targeting large market indications.

The firm is looking for companies with experienced management teams and prefer working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and is open to either lead or co-invest in rounds. The firm generally looks to take a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: China-Backed Investor Group Seeks Medical Device, Data and Health Monitoring Opportunities

An investor group based out of New York, USA with financial backing from China in looking at US-based opportunities that they believe will translate well to the Chinese market. These opportunities do not need to already have traction in China since the firm hopes to be a Chinese partner to help them access and succeed in these markets in addition to being an investor. The firm expects to make 20-50 investments this year and is prioritizing investments in the $10-50 million USD range, but is also willing to look at earlier stage opportunities.

The firm is interested in medical devices. Specifically, medical devices related to senior care, health planning, data collection, data analysis and management, 24/7 patient monitoring systems, and devices that can help facilitate conversations between patients and caregivers. Companies they’ve worked with and still have interest for include: laser treatment devices for arthritis, devices for rehabilitation, and devices for surgery. The firm is generally less interested in pure healthcare IT. For device companies, the firm prefers that they already have FDA approval, but are willing to look at companies who are close to completing FDA pivotal trials as well.

The firm prefers companies that are ideally already revenue generating, but they are also willing to look at companies that are near revenue generation. The firm wants to work with companies who are interested in accessing the Chinese market and are willing to form a joint venture with the firm in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: Corporate Venture Fund Invests in Therapeutics, Devices and HCIT for Cardiovascular Diseases, Pain, Kidney Diseases and More

A diversified business based in Japan has opened US corporate venture offices in Massachussets and California. The corporate venture fund has an evergreen structure looking to allocate between $1-$3 million per deal initially and up to $5 million over the life of the investment. The firm seeks to invest in approximately 2-4 companies over the next 12 months and are open to investing in companies across the globe.

Sectors of interest include: pharmaceuticals, medical device and digital health. Therapeutic and product areas of interest include: Pain, critical care, cardiovascular disease, musculoskeletal disease, kidney disease, patient monitoring technologies, bioprocessing technologies, digital therapeutics. The firm is open to all stages of investment, with a general preference toward companies with at least some early clinical data.

The firm invests in private companies and is willing to work with all types of management teams including incomplete teams. They generally request at least an observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Big Data in Drug Discovery: 5 Experts Share Their Thoughts at RESI Boston

By Michael Quigley, VP of Investor Research, LSN

mike-2To reduce the massive costs associated with getting a new drug approved, many startups, large pharma companies, venture funds, and others are looking to big data for a solution. These firms are researching, partnering, and investing into machine learning and artificial intelligence systems that scour through massive drug and target libraries to more quickly identify potential candidates than a team of researchers could. These technologies are leveraging all kinds of scientific and medical data including chemical, biologic, genomic and clinical datasets to best identify candidates. Companies are touting their tech promises “years” of savings and lower failure rates in research that can now be done through advanced algorithms. This may seem like quite the promise, but if you look at the number and size of deals in the space just in the past year, it’s clear that big players are listening (1, 2, 3, 4, 5, 6).

At RESI Boston this September 26th we are bringing together a panel of 5 experts in this space to discuss their thoughts on the challenges and opportunities that the use of Big Data in Drug Discovery currently faces. These speakers include a promising company with an emerging drug discovery technology, a massive CRO, and three venture funds, all actively working in this space. Look below to see the speakers for yourself. This is another cutting-edge session you won’t want to miss!

  • Richard Soll, Senior Vice President, Research Service Division, WuXi AppTec (moderator)
  • Gini Deshpande, Founder and Chief Executive Officer, NuMedii, Inc.
  • Millie Liu, Founding Partner, Managing Director, Procyon Ventures
  • Dylan Morris, Partner, CRV
  • Annie Hazlehurst, Founder, Faridan
  1. http://www.fiercebiotech.com/medtech/gsk-taps-baltimore-s-insilico-for-ai-based-drug-discovery
  2. https://www.reuters.com/article/us-astrazeneca-ai-berg/astrazeneca-taps-ai-for-drug-discovery-in-deal-with-berg-idUSKCN1B81G1
  3. http://www.koreabiomed.com/news/articleView.html?idxno=1254
  4. http://www.prnewswire.com/news-releases/wuxi-nextcode-ai-points-to-new-therapeutic-approaches-to-cardiovascular-disease-and-cancer-in-yale-nature-study-300457412.html
  5. http://www.wired.co.uk/article/benevolent-ai-london-unicorn-pharma-startup
  6. http://www.prnewswire.com/news-releases/numedii-inc-announces-new-partnership-to-discover-and-advance-new-treatments-for-idiopathic-pulmonary-fibrosis-300437651.html

How to Get the Most Out of Life Science Partnering Events

By Lucy Parkinson, Director of Research, LSN

RESI Boston is approaching, and partnering requests are flying back and forth between attendees. As this is the 14th RESI event, LSN has gathered a great deal of information and insight on the partnering process. We’ve seen how skilled entrepreneurs take steps to increase their partnering success. Based on our observations, here are a few keys to partnering success:

Numbers Are Key

A simple truth underlies a lot of our other insights: Entrepreneurs that send more requests get more meetings. However, those requests have to be directed at relevant investors. The below chart plots the relationship between the number of requests sent via RESI Partnering and the number of meetings booked. This makes it clear that your goal is to surface as many relevant investors at the partnering event as possible and provide them with a clear reason to meet with you.

Make A Target List

Many partnering events claim a high number of investor attendees, but what’s important is to find out which of those investors are potentially relevant for your opportunity. The RESI website includes a list of investors that are signed up to attend, and LSN’s Research team speaks to all those investors prior to the event in order to understand their investment interests and criteria. RESI attendees can therefore search RESI Partnering to get a complete view of the most relevant attending investors. At other events, the partnering system may not provide this information as consistently — you may need to do your homework on the attending investors. A search online for their portfolios and stated interests should reveal which are most relevant for you.

Log In Early and Often

As a partnering event approaches, investors will find many meeting requests in their system inbox. Some investors like to look at those requests as soon as they come in, and may fill up their schedule with interesting startups quite early. However, it’s more common for investors to select their meetings close to the event — and some investors only sign up for events at the last minute. There’s therefore an advantage to getting a set of requests out as soon as the system opens to catch the earlybirds; however, running regular searches to look for new attendees as the event approaches will allow you to identify new targets and increase your meeting count.

Don’t Limit Your Investor Universe

At RESI, we welcome a broad variety of investors, including venture capital firms, big pharma, family offices, venture philanthropy funds, angels, and many more. Any of these investors could potentially be a fit for your round. As we covered in last week’s Next Phase, some entrepreneurs make the mistake of focusing only on the top 25 big name VC funds. If one of these funds has an investment staff member at the event, it’s definitely worth shooting them an invite, but if you only send requests to attendees from these firms, you’re likely to lose a large part of the value of the event. Partnering events are a great opportunity to broaden your network; the most relevant firms represented at the event might be those you’ve never heard of or those who you hadn’t previously considered approaching for investment. Equally, don’t dismiss a firm because they’re based far from your headquarters; many international investors attend partnering events specifically because they want to broaden their exposure to overseas deal flow.

Write A Clear Intro Message and Profile

You’d be surprised how many CEOs send partnering requests with only a one-sentence message, or no message at all. Similarly, many may neglect to fill out their profiles, or forget to update their pre-loaded profiles from last year’s event. It’s important to keep in mind that the investor will have received a deluge of meeting requests, and if you don’t make your company’s relevance immediately clear, they will move on to the next request. Make sure that your message clearly describes what your company does and why it’s aligned with that particular investor’s interests, and be sure that if they click through to your profile they’ll have access to all the vital information needed to determine that you are a fit for their firm.

Follow Up On Your Requests

To maximize your partnering success, you should reach beyond the partnering system. For each investor on your target list at the event, try to find further contact info. Send an email or make a quick call to tell them what your company does and why you’re highly interested in meeting with them at the event. With so many messages to go through, an extra nudge may be necessary to direct the investor’s attention to your company. For RESI Boston, we’ve therefore created the new RESI Premier Partnering Plus Registration which provides investor contact info in order to help entrepreneurs follow up on their meeting requests.

RESI is approaching on September 26th – if you would like to put this advice to work and start filling out your meeting schedule, register now.

Hot Investor Mandate 1: Large Financial Firm Invests in Clinical Stage Therapeutics, Medical Devices and Diagnostics

Yuanta Asia Investment is an investment firm based in Taiwan. The firm is the subsidiary of Yuanta Securities, a Taiwanese securities house with approximately USD 6.8 billion AUM and subsidiary of Yuanta Financial Holdings. The firm engages in M&A, underwriting, as well as direct investments. The firm is interested in the life sciences and will target new investments from a new USD 100 million fund. The firm can sometimes leverage different funds to invest. The fund’s target investment size is USD 3-5 million per company in average, USD 5-15M for pre-IPO round and USD 1-1.5 million for early stage companies. Capital allocation per company will not exceed 10% of the fund. The firm seeks companies in Asia-Pacific, including the US and Japan. The firm is actively seeking new investment opportunities.

In the life sciences, the firm is interested in therapeutics, medical devices, and diagnostics. For therapeutics, the firm will consider a broad range of modalities including small molecules and biologics with an emphasis on immunotherapy or other breakthrough technology in CNS related disease. The firm is opportunistic in terms of indications. For companies in Asia, the firm is agnostic to the phase of development. For overseas deals, the firm is currently looking for preclinical to phase 2 assets. The firm prefers candidates with in-human data and are conducting clinical trials in the US, while this is not a requirement.

For devices, the firm considers minimally invasive class III devices in the cardiovascular and cancer space that have prototype and have obtained proof-of concept. For diagnostics, the firm is interested in genomics and big data analytics. Recently there is an interest in the cosmetics and supplements area, and the firm is seeking acquisition opportunities to commercialize products through distribution channels within its network. The firm is also looking for the target in pre-IPO round of placement in NASDAQ or other market.

The firm only invests in private companies and looks to hold less than 15 percent of total shares of the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com